Wedbush Lowers Earnings Estimates for Intellia Therapeutics

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at Wedbush dropped their Q3 2025 earnings estimates for shares of Intellia Therapeutics in a report issued on Thursday, August 7th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.96) for the quarter, down from their previous forecast of ($0.80). Wedbush has a “Neutral” rating and a $7.00 price objective on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Wedbush also issued estimates for Intellia Therapeutics’ Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.94) EPS, Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($1.04) EPS, Q3 2026 earnings at ($1.13) EPS, Q4 2026 earnings at ($1.22) EPS, FY2026 earnings at ($4.36) EPS, FY2027 earnings at ($3.02) EPS, FY2028 earnings at ($2.80) EPS and FY2029 earnings at ($2.59) EPS.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.04. The company had revenue of $14.25 million for the quarter, compared to analyst estimates of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 54.90%. The business’s quarterly revenue was up 104.3% on a year-over-year basis. During the same period last year, the business posted ($1.52) EPS.

Other analysts have also issued reports about the stock. HC Wainwright decreased their price target on shares of Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday. Canaccord Genuity Group decreased their price target on shares of Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating on the stock in a research report on Tuesday, June 3rd. Citigroup decreased their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating on the stock in a research report on Friday, May 9th. Chardan Capital decreased their target price on shares of Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $45.00 target price (down from $50.00) on shares of Intellia Therapeutics in a research report on Friday. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $30.68.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $10.74 on Monday. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -2.29 and a beta of 2.31. The company’s fifty day moving average is $10.62 and its two-hundred day moving average is $9.48. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $24.16.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 7,462 shares of the business’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the sale, the executive vice president directly owned 106,062 shares of the company’s stock, valued at $1,486,989.24. The trade was a 6.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 12,534 shares of company stock worth $153,837 over the last ninety days. Insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Cambridge Investment Research Advisors Inc. grew its holdings in Intellia Therapeutics by 51.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock valued at $140,000 after purchasing an additional 6,722 shares during the period. D.A. Davidson & CO. grew its holdings in Intellia Therapeutics by 76.2% during the first quarter. D.A. Davidson & CO. now owns 26,020 shares of the company’s stock valued at $185,000 after purchasing an additional 11,250 shares during the period. California State Teachers Retirement System grew its holdings in Intellia Therapeutics by 4.1% during the fourth quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock valued at $1,057,000 after purchasing an additional 3,596 shares during the period. Raymond James Financial Inc. acquired a new position in Intellia Therapeutics during the fourth quarter valued at approximately $4,793,000. Finally, Baker BROS. Advisors LP acquired a new position in Intellia Therapeutics during the fourth quarter valued at approximately $7,510,000. 88.77% of the stock is owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.